Erasca (ERAS) EBITDA Yield: History & Chart

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T19:21:39.594Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:21:39.594Z.

Quote observation: 2026-10-06T19:20:21.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -149,743,000
Quote market capitalization: 4,938,506,404
Total debt · period ending 2026-06-30: 44,714,000
Cash · period ending 2026-06-30: 42,542,000

FMP input reference: f97479f440d7a03605f533a56e26179237db48e588053495707f458dff3bcd44

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

ERAS EBITDA Yield Metrics

EBITDA YIELD

N/A

ERAS Competitors' EBITDA Yield

ERAS

Erasca, Inc.

Current

Market Cap

$4.94B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

WAY

Waystar Holding Corp.

vs ERAS

Market Cap

$5.00B

EBITDA Yield

6.68%

TTM Avg

6.48%

3Y Avg

5.36%

5Y Avg

5.36%

MMSI

Merit Medical Systems, Inc.

vs ERAS

Market Cap

$5.07B

EBITDA Yield

6.20%

TTM Avg

6.37%

3Y Avg

5.19%

5Y Avg

4.76%

ORKA

Oruka Therapeutics, Inc.

vs ERAS

Market Cap

$4.81B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MIRM

Mirum Pharmaceuticals, Inc.

vs ERAS

Market Cap

$4.78B

EBITDA Yield

N/A

TTM Avg

0.05%

3Y Avg

0.05%

5Y Avg

0.05%

SRRK

Scholar Rock Holding Corporation

vs ERAS

Market Cap

$5.10B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COGT

Cogent Biosciences, Inc.

vs ERAS

Market Cap

$5.14B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TVTX

Travere Therapeutics, Inc.

vs ERAS

Market Cap

$5.18B

EBITDA Yield

0.40%

TTM Avg

0.34%

3Y Avg

0.34%

5Y Avg

0.34%

DNTH

Dianthus Therapeutics, Inc.

vs ERAS

Market Cap

$4.70B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LFST

LifeStance Health Group, Inc.

vs ERAS

Market Cap

$4.68B

EBITDA Yield

2.86%

TTM Avg

2.61%

3Y Avg

2.07%

5Y Avg

1.96%

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Erasca, Inc. (ERAS)	$4.94B	N/A	N/A	N/A	N/A
Waystar Holding Corp. (WAY)vs ›	$5.00B	6.68%	6.48%	5.36%	5.36%
Merit Medical Systems, Inc. (MMSI)vs ›	$5.07B	6.20%	6.37%	5.19%	4.76%
Oruka Therapeutics, Inc. (ORKA)vs ›	$4.81B	N/A	N/A	N/A	N/A
Mirum Pharmaceuticals, Inc. (MIRM)vs ›	$4.78B	N/A	0.05%	0.05%	0.05%
Scholar Rock Holding Corporation (SRRK)vs ›	$5.10B	N/A	N/A	N/A	N/A
Cogent Biosciences, Inc. (COGT)vs ›	$5.14B	N/A	N/A	N/A	N/A
Travere Therapeutics, Inc. (TVTX)vs ›	$5.18B	0.40%	0.34%	0.34%	0.34%
Dianthus Therapeutics, Inc. (DNTH)vs ›	$4.70B	N/A	N/A	N/A	N/A
LifeStance Health Group, Inc. (LFST)vs ›	$4.68B	2.86%	2.61%	2.07%	1.96%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

ERAS EBITDA Yield Metrics

ERAS Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics